Log in
E-mail
Password
Show password
Remember
Forgot password ?
Become a member for free
Sign up
Sign up
New member
Sign up for FREE
New customer
Discover our services
Settings
Settings
Dynamic quotes 
OFFON
News: Latest News
Latest NewsCompaniesMarketsEconomy & ForexCommoditiesInterest RatesBusiness LeadersFinance Pro.CalendarSectors 
All NewsEconomyCurrencies & ForexEconomic EventsCryptocurrenciesCybersecurityPress Releases

Gilead Sciences wins reversal of $1.2 billion award in patent case with Bristol Myers

08/26/2021 | 02:25pm EDT
FILE PHOTO: Gilead Sciences Inc pharmaceutical company is seen during the outbreak of the coronavirus disease (COVID-19), in California

(Reuters) - A U.S. appeals court on Thursday threw out a $1.2 billion ruling against Gilead Sciences Inc, finding a patent on a cancer therapy it was accused of infringing was invalid, in a blow to rival Bristol Myers Squibb Co.

The two companies have been embroiled in a case involving accusations that Yescarta, the CAR-T cell cancer immunotherapy from Gilead's Kite Pharma unit, infringed on a patent for a similar therapy from Bristol's Juno Therapeutics.

Last year, a federal judge increased the damages from a jury trial and ordered Gilead to pay Bristol Myers $1.2 billion in the patent infringement case. The ruling on Thursday by the U.S. Court of Appeals for the Federal Circuit reversed the decision.

Bristol Myers in a statement said it disagreed with latest ruling and would seek a review of the Federal Circuit's decision.

Gilead and Kite's attorney Josh Rosenkranz of Orrick Herrington & Sutcliffe did not immediately respond to a request for comment.

Gilead shares were up 0.3%, while Bristol shares were off 0.5% in midday trading.

The Gilead drug, Yescarta, belongs to a class of cutting-edge cancer treatments known as chimeric antigen receptor T-cell therapy, or CAR-T, which reprograms the body's own immune cells to recognize and attack malignant cells.

Gilead bought Kite Pharma, which developed Yescarta, for $11.9 billion in 2017, with the treatment securing U.S. approval that year. It recorded sales of $338 million in the first six months of this year.

A jury in 2019 found that Kite willfully infringed and awarded Juno and Memorial Sloan Kettering Cancer Center in New York, which licenses the patent to Juno, $778 million. U.S. District Judge Philip Gutierrez increased the award to $1.2 billion in Los Angeles federal court last year.

Memorial Sloan Kettering did not immediately respond to a request for comment.

Bristol Myers acquired Juno and its CAR-T program with its $74 billion purchase of Celgene in 2019.

Chief U.S. Circuit Judge Kimberly Moore wrote for a unanimous three-judge panel that the relevant parts of Juno's patent were invalid because they lacked a sufficient written description and details.

Moore was joined by Circuit Judges Sharon Prost and Kathleen O'Malley in the ruling.

During a July oral argument https://www.reuters.com/legal/transactional/fed-circ-probes-validity-cancer-treatment-patent-12-bln-win-2021-07-06, Moore compared the patent's description to trying to identify a specific car by saying it has four wheels.

This story corrects paragraph 1 and 2 to show one patent, not patents.

(Reporting by Ankur Banerjee in Bengaluru and Blake Brittain in New York; Editing by Bill Berkrot)

By Blake Brittain and Ankur Banerjee


© Reuters 2021
Latest news "Economy & Forex"
06:08aNigeria to launch digital currency on Monday, central bank says
RE
06:06aROCKY MOUNTAIN HIGH : U.S. looks to Colorado for methane emissions policy
RE
05:32aCOVID-19 cases recorded in eastern Europe hit 20 million
RE
05:27aSunak says inflation, rates feed into budget thinking
RE
05:07aSaudi energy minister says will ship hydrogen in due course
RE
04:58aCoronavirus cases in eastern europe surpass 20 million - reuters tally
RE
04:53aSaudi energy minister says he will not buy electric car but saudi arabia will manufacture electric vehicles
RE
04:47aChina's debt-ridden Evergrande resumes work on more than 10 property projects
RE
04:14aAustralian coalition gov't junior partner gives preliminary support for net zero
RE
03:47aSaudi energy ministry building artificial intelligence team with multibillion riyal budget - ministry official at youth green summit
RE
Latest news "Economy & Forex"